Table 2 List of manuscripts reporting data about response to treatment of patients with CNO
From: Dealing with Chronic Non-Bacterial Osteomyelitis: a practical approach
Reference | Nr. patients | Treatment | Response to treatment |
|---|---|---|---|
Wipff J et al., 2015 [20] | 178 | NSAIDs | 126/178 (71%): clinical response |
Sulfasalazine | 7/17 (41%): clinical response | ||
Methotrexate | 3/8 (37%): clinical response | ||
Bisphosphonates | 6/8 (75%): clinical response | ||
Anti-TNFα | 8/9 (89%): clinical response | ||
Jansson A et al., 2007 [24] | 89 | NSAIDs | 64/77 (83%): clinical response |
Steroids | 13/13 (100%): transient response | ||
DMARDs | 6/6 (100%): no response | ||
PAM | 1/4 (25%): clinical response | ||
1/4 (25%:) partial response | |||
2/4 (50%): no response | |||
Kaiser D et al., 2015 [45] | 41 | NSAIDs | 21/37 (57%): clinical response |
Methotrexate | 6/7 (86%): no response | ||
Bisphosphonates | 1/5 (20%): clinical response | ||
1/5 (20%): partial response | |||
Etanercept | 2/8 (25%): clinical response | ||
Beck C et al., 2010 [33] | 37 | Naproxene | 16/37 (43%) clinical response |
Indomethacin | 4/7 (57%) clinical response | ||
Diclofenac | 9/12 (75%) clinical response | ||
Others NSAIDs | 6/19 (32%) clinical response | ||
Sulfasalazine | 4/5 (80%) clinical response | ||
Steroids | 4/4 (100%) clinical response but recurrence during dosage tapering | ||
Roderick M et al., 2014 [40] | 11 | PAM | 8/11 (73%) clinical response |
Miettunen PM et al., 2009 [46] | 9 | PAM | 9/9 (100%) clinical and radiological response |
Gleeson H et al., 2008 [39] | 7 | PAM | 6/7 (86%) clinical response |
Hospach T et al., 2010 [47] | 7 | PAM | 7/7 (100%) clinical response and radiological improvement |
Kerrison C et al., 2004 [48] | 7a | PAM | 7/7 (100%) clinical remission |
Batu ED, et al., 2015 [49] | 5 | Etanercept | 5/5 (100%) clinical response |
Simm PJ et al., 2008 [37] | 5 | PAM | 4/5 (80%) clinical response and radiological improvement |
Eleftheriou D et al., 2010 [50] | 4 | anti-TNFα | 2/3 clinical response to infliximab, 1/3 response to adalimumab |